The comparative periods are not comparable due to 31 December 2024 (FY24) covering only six months whilst 31 December 2025 (FY25) reflects a twelve month period.
Diluted HEPS of 19.1cps for FY25 (FY24: -5.4cps).
Gross revenue from continuing operations of R7 303m (FY24: R3 765m). On a comparable basis, revenue declined by c. 10% y-y.
Expenses of R6 257m (FY24: R2 673m). Expense-to-sales of 85.7% in FY25 (FY24: 71.0%).
OPM of -7.0% (FY24: 6.5%).
No dividend (FY24: 6.0cps).
Net cash rose from R348m to R607m in FY25, while gross increased from R619m to R627m in FY25.
AfroCentric Health (RF) Proprietary Limited disposed of its entire interest in ADS, along with its wholly owned subsidiaries Tendahealth Proprietary Limited (Tendahealth) and AfroCentric Financial Services Proprietary Limited (AFS) to Sanlam Life for R2.8 million.
Medscheme Limited disposed of its entire interest in Wellworx to Sanlam Life for R12.2 million.
AfroCentric entered into an agreement to dispose of the Activo Group. Commercial terms were agreed on 23 December 2025 with FHC Proprietary Limited to dispose of 100% of the shares held in Activo.
